Vol. I — Est. 2024

The stories behind
the molecules
that change everything.

Patent cliffs. FDA advisory committees.
Reformulations that reshape therapeutic categories overnight.

SCROLL

The Archive

From origin to present dispatch.

Full Archive →

Pharmaceutical research documents and molecular structure diagrams on a desk

AdvisoryVol. I, No. 1

Why This Archive Exists: On the Silence Between the Approval Letter and the Press Release

The FDA approves a drug. A press release goes out. A stock price moves. But between those two events lies the actual story — the advisory committee vote, the label negotiation, the post-marketing commitment buried in footnote twelve. Formulary was built to read those footnotes aloud. This is not a newsletter. It is a pharmacopoeia of the industry's own making, annotated by the people who live inside it.

January 2024·8 min read

Read the Full Brief →

Close-up of pharmaceutical capsules and molecular model in laboratory setting

Patent WatchVol. I, No. 4

The Humira Cliff Nobody Predicted Would Take This Long to Land

Adalimumab biosimilar launches were supposed to reshape the rheumatology formulary by mid-2023. They did — just not in the direction payers expected. Authorized generics, rebate walls, and patient assistance program enrollment created a thicket that delayed meaningful formulary displacement by eleven months. The playbook is now being studied by every large-molecule patent holder with an expiry inside the next four years.

March 2024·11 min read

Read the Full Brief →

RegulatoryVol. I, No. 6

PDUFA Dates as Calendar Events: What the Advisory Committee Vote Trajectory Tells You Before the Letter Arrives

Every PDUFA date is a known unknown. The approval letter arrives on schedule; the label does not. Medical affairs teams that treat the advisory committee transcript as required reading — not background material — consistently identify the label restriction risk three to six weeks before competitors. This brief maps the signal patterns across sixty-two adcom votes from 2021 to 2024.

April 2024·14 min read

Read the Full Brief →

Laboratory researcher examining drug compound under microscope

PipelineVol. I, No. 9

GLP-1 Pipeline Density and the Quiet Cannibalization of Cardiovascular Formularies

Semaglutide's cardiovascular outcomes data did not just expand an indication. It began reclassifying obesity as a cardiovascular condition — a shift with formulary implications that most pharmacy benefit managers have not yet fully priced into their 2025 contracts. Meanwhile, eight additional GLP-1 agents are in Phase III, each with differentiated dosing profiles that will force payer step-therapy criteria into uncomfortable territory.

June 2024·16 min read

Read the Full Brief →

"The label restriction risk is visible in the advisory committee transcript weeks before the approval letter arrives. Most teams are not reading the transcript."

— Formulary, Vol. I No. 6

PricingVol. II, No. 2

The IRA's Drug Negotiation List and the Therapeutic Categories That Will Never Look the Same

The first ten drugs selected for Medicare price negotiation were not chosen randomly. The selection logic — spend volume, lack of generic competition, therapeutic alternatives — is now the operating framework for every launch team filing a new drug application. This dispatch examines how the negotiation list is already reshaping pipeline prioritization at three mid-size specialty pharma companies.

August 2024·13 min read

Read the Full Brief →

FDA regulatory documents and pharmaceutical approval paperwork on office desk

RegulatoryVol. II, No. 5

Orphan Drug Designation: The Regulatory Tool That Became a Business Model

Seven-year market exclusivity was designed to incentivize research into rare diseases affecting fewer than 200,000 Americans. It became, over two decades, the most reliably modeled revenue protection strategy in specialty pharma. FDA's 2024 guidance tightening prevalence verification requirements is the first structural check on the designation in fifteen years — and it is arriving as the orphan pipeline is more crowded than at any point in the law's history.

October 2024·10 min read

Read the Full Brief →

Patent WatchVol. II, No. 8

Reformulation as Defense: The Quiet Science of Extended-Release Conversion

When a blockbuster's primary patent expires, the product development team does not stand down. It pivots to formulation chemistry — extended-release coatings, abuse-deterrent matrices, fixed-dose combinations — each carrying its own patent estate and, more importantly, its own therapeutic substitution barrier. This brief catalogs twelve reformulation launches from the past three years and scores their payer formulary displacement resistance.

November 2024·9 min read

Read the Full Brief →

Molecular structure model of pharmaceutical compound on laboratory bench

PipelineVol. III, No. 1

The PCSK9 Inhibitor Market at Year Six: A Formulary Postmortem

Evolocumab and alirocumab launched with cardiovascular outcomes data, mechanism novelty, and enormous clinical enthusiasm. Payers responded with prior authorization criteria so restrictive that real-world utilization ran at roughly eight percent of the eligible population for three years. The story of how that changed — and what changed it — is the most instructive case study in specialty formulary access that the industry produced in the decade.

January 2025·18 min read

Read the Full Brief →

"A generic launch date is not a fact. It is a negotiated position between innovator counsel, ANDA filers, and the economic incentives of an authorized generic agreement."

— Formulary, Vol. III No. 4

PricingVol. III, No. 4

Generic Launch Dates and the Eighteen-Month Shift Nobody Announced

The authorized generic agreement between Teva and a major innovator was filed on a Friday afternoon. By Monday, three pharmacy benefit managers had quietly adjusted their 2026 formulary models. The launch date had moved eighteen months. This is not an unusual story — it is the operating rhythm of generic market formation, largely invisible to everyone except the people whose job is to watch for it. This brief explains the document trail.

March 2025·12 min read

Read the Full Brief →

Pharmacist reviewing drug safety documentation at pharmacy counter

AdvisoryVol. III, No. 7

Reading the REMS: When Risk Mitigation Becomes a Distribution Moat

Risk Evaluation and Mitigation Strategies exist to protect patients. They also, in several well-documented cases, protect market share. When a REMS requires certified prescriber enrollment, pharmacy dispensing registration, and patient acknowledgment forms, the friction it creates is identical whether the intent is safety or competition suppression. The FTC has noticed. So have six state attorneys general.

May 2025·15 min read

Read the Full Brief →